Genmab — Share Issue/Capital Change 2017

Aug 15, 2017

Company Announcement

Copenhagen, Denmark; August 15, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) will
increase its share capital by 21,070 shares as a consequence of the exercise of
employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 250 shares at DKK 66.60,
-- 125 shares at DKK 98,
-- 1,000 shares at DKK 174,
-- 250 shares at DKK 210,
-- 2,000 shares at DKK 225.90,
-- 1,750 shares at DKK 234,
-- 400 shares at DKK 246,
-- 1,620 shares at DKK 254,
-- 5,000 shares at DKK 272,
-- 1,175 shares at DKK 326.50,
-- 125 shares at DKK 329,
-- 4,375 shares at DKK 337.40 and
-- 3,000 shares at DKK 939.50.

Proceeds to the company are approximately DKK 7.7 million. The increase
corresponds to approx. 0.03% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2017. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish Business
Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 10 of Executive Order no. 1526 of December 9, 2016 on
Issuers' Disclosure Obligations, it is hereby announced, that the total nominal
value of Genmab A/S' share capital after the capital increase is DKK
61,139,472, which is made up of 61,139,472 shares of a nominal value of DKK 1
each, corresponding to 61,139,472 votes.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
DARZALEX® (daratumumab) for the treatment of certain multiple myeloma
indications, and Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications. Daratumumab is in clinical development for
additional multiple myeloma indications, other blood cancers, and solid tumors.
A subcutaneous formulation of ofatumumab is in development for relapsing
multiple sclerosis. Genmab also has a broad clinical and pre-clinical product
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody® platform which creates effector
function enhanced antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 27
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark